Published in Vaccine Weekly, April 30th, 2008
The first use of a live listeria cancer vaccine in man: Abstract 225
Phase I/II trial results have shown that the live Listeria cancer vaccine, Lovaxin C, is safe for humans. In addition, three women in the cervical cancer trial had approximately 20 percent tumor reductions, researchers report.
"We are using Listeria to deliver...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly